Navigation Links
Renova Therapeutics appoints Richard 'Mac' McCloskey to head company's clinical development efforts
Date:1/14/2016

SAN DIEGO, Jan. 14, 2016 /PRNewswire-USNewswire/ -- Renova™ Therapeutics, a biopharmaceutical company developing gene therapy treatments for congestive heart failure and other chronic diseases, has hired Richard 'Mac' McCloskey, M.D., as Executive Vice President of Clinical Development.

An author of more than 100 peer-reviewed papers and editorials as well as three books, Dr. McCloskey has led an illustrious career in medical research and clinical practice. He has directed registration trials for Hoffman LaRoche and Centocor and was, most recently, Vice President of Scientific Affairs at Johnson & Johnson Development Corporation as well as a scientific adviser to Endo Pharmaceuticals.

Richard 'Mac' McCloskey, MD, joins Renova Therapeutics as Executive Vice President of Clinical Development.
Richard 'Mac' McCloskey, MD, joins Renova Therapeutics as Executive Vice President of Clinical Development.

As Executive Vice President of Clinical Development for Renova Therapeutics, Dr. McCloskey will be responsible for all clinical aspects of the company's trials, including preparation of trial synopses and protocols, review and approval of case report systems and safety reporting, and drafting of clinical trial endpoints. He will also ensure Renova Therapeutics meets all regulatory requirements for clinical trial safety reporting, and, as needed, will present trial data to regulatory agencies.

In this role, Dr. McCloskey will work closely with the Senior Vice President of Regulatory Affairs and Quality Assurance and will coordinate with the company's expert consultants on statistical analysis, trial planning and conduct. His immediate focus will be on Renova Therapeutics' lead investigational product RT-100, a single-dose gene therapy for the treatment of congestive heart failure, which recently completed a Phase 2 clinical trial.

"We're excited to have Mac join Renova as we progress further with our product pipeline," said Jack W. Reich, Ph.D., CEO and Co-founder of Renova Therapeutics. "His contributions in the medical field and in clinical development will be a tremendous asset to our team, as we continue to develop a portfolio of gene therapies for cardiovascular and metabolic diseases."

Dr. McCloskey received a master's in microbiology and an M.D. from the University of Rochester and completed his medical training at Duke University and the National Institutes of Health. He has been on the faculty of the University of Texas, the University of Pennsylvania and Jefferson Medical College, and he is an emeritus fellow of the American College of Physicians and the Infectious Disease Society of America.

His FDA-approved submissions include interferon, ceftriaxone, infliximab, abciximab, midazolam and injectable testosterone. He also contributed to the following as an academic clinical investigator: cefoxitin, thienamycin, cefotaxime, mezlocillin, ticarcillin, imipenem-cilastatin, cefmenoxime, amdinocillin, fleroxacin and ofloxacin.

To him, taking on this role is personal: "Having been treated for congestive heart failure by the single procedure of surgical aortic valve replacement, I have both a personal and scientific appreciation of the breakthrough potential of a single treatment for CHF," says McCloskey. "And the data derived so far for RT-100 demonstrates that potential."

About Renova Therapeutics
Renova™ Therapeutics is developing definitive, one-time gene therapy treatments to restore the health of people suffering from chronic diseases. The first two indications the company is pursuing are therapies for congestive heart failure (CHF) and type 2 diabetes, two of the most common and devastating chronic diseases in the world. The company's lead investigational product, RT-100, is a new type of treatment that delivers a therapeutic gene directly to damaged heart tissue during a routine outpatient procedure and has the potential to renew heart function in millions of patients with CHF. The company's product pipeline also includes a second-generation therapy for CHF patients and a groundbreaking therapy in pre-clinical stage for sufferers of type 2 diabetes. Renova Therapeutics was founded in 2009 and is led by an experienced management team in biopharmaceuticals and gene therapy. For additional information about the company, please visit www.renovatherapeutics.com.

Photo - http://photos.prnewswire.com/prnh/20160112/321689
Logo - http://photos.prnewswire.com/prnh/20151231/318660LOGO


'/>"/>
SOURCE Renova Therapeutics
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round
2. ViveBio, LLC Enters Worldwide Exclusive Licensing Agreement with Renovar Inc. for Novel Urine Based Biomarker Technologies Covering Kidney Disease and Transplant Monitoring
3. Renova Therapeutics recruits seasoned expert to lead companys regulatory and quality efforts
4. Renova Therapeutics expands robust gene therapy intellectual property portfolio for cardiovascular and metabolic disease treatments
5. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
6. Novelos Therapeutics Provides Product Pipeline Update
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
8. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
9. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
10. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
11. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... ... 31, 2020 , ... As one of the most prominent and popular Houston ... City, TX, with a wide range of professional dental services for many years. The ... that is not far from the previous clinic location. Dr. Simone Ellis’s modern, cutting-edge ...
(Date:7/31/2020)... ... July 31, 2020 , ... A June 29 ... was believed to have been caused by tiny worms that inhabited the mouths of ... myth including details of small creatures that are commonly found in water supplies. Marina ...
(Date:7/22/2020)... Ore. (PRWEB) , ... July 22, 2020 , ... ... safely re-open schools is a critical topic receiving national attention. A new 8 ... critical issue for creating and maintaining safe schools. , The Germ-Fogger™ disinfecting-fogger is ...
Breaking Medicine Technology:
(Date:8/11/2020)... , ... August 11, 2020 , ... ... addressing unmet needs in the field of urology, today announced that Sean Delair, ... of Excellence. The designation recognizes that Dr. Delair has achieved a high level ...
(Date:8/7/2020)... , ... August 07, 2020 , ... ... released the Physician Fee Schedule proposed rule for the 2021 calendar year. The ... by devaluing the procedures they perform which help return patients suffering from joint ...
(Date:8/5/2020)... ... 05, 2020 , ... In its often-heroic ongoing response to ... of the obstacle - shortages of tests, ventilators and ICU beds; strained lab ... postponement of all nonessential services - providers across the country have found new ...
(Date:8/5/2020)... Africa (PRWEB) , ... August 05, 2020 , ... Today, ... Africa , the leading trade and investment platform for Africa, announced that they have ... for YPO Africa and Invest Africa to support each other in their African impact ...
(Date:8/3/2020)... ... August 03, 2020 , ... WorkBook6 ... its newest product, CoverageCoach. The site provides a simple and efficient way for ... The company sees CoverageCoach as an important expansion for the insurance marketing ecosystem, ...
Breaking Medicine News(10 mins):